Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Reumatol. clín. (Barc.) ; 14(5): 303-306, sept.-oct. 2018. ilus, tab
Artigo em Espanhol | IBECS | ID: ibc-175994

RESUMO

La enfermedad por arañazo de gato (EAG) es una enfermedad infecciosa causada por la proteobacteria Bartonella henselae, caracterizada por fiebre y linfadenopatía granulomatosa. La inmunosupresión es un factor de riesgo para el desarrollo de formas atípicas de la enfermedad. Presentamos el caso de una mujer de 52 años de edad que presentó fiebre y adenomegalias inguinales bilaterales. No tenía contacto aparente con animales. La paciente estaba recibiendo tratamiento con etanercept por artritis reumatoidea. La biopsia del ganglio linfático informó de una adenopatía granulomatosa. Evolucionó favorablemente con la interrupción de etanercept y el tratamiento con minociclina. Presentó remisión clínica y la seroconversión típica. La infección por Bartonella debería ser considerada como un diagnóstico diferencial en pacientes con artritis reumatoidea, con linfadenopatía de origen desconocido


Cat scratch disease (CSD) is an infectious disorder caused by Bartonella henselae and characterized by fever and granulomatous lymphadenopathy. Immunosuppression is a risk factor for the development of atypical forms of the disease. We report the case of a 52-year-old woman who presented with fever and bilateral inguinal lymph node enlargement. She did not have apparent contact with animals. The patient was receiving etanercept therapy for rheumatoid arthritis. Lymph node biopsy demonstrated granulomatous lymphadenitis. She was successfully managed by discontinuing etanercept and by treatment with minocycline. She developed clinical remission and typical seroconversion. Infection with Bartonella should be considered in the differential diagnosis in rheumatoid arthritis patients with lymphadenopathy of unknown origin


Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Artrite Reumatoide/complicações , Doença da Arranhadura de Gato/diagnóstico , Etanercepte/efeitos adversos , Minociclina/uso terapêutico , Terapia Biológica/efeitos adversos , Diagnóstico Diferencial , Infecções por Bartonella/transmissão
2.
Reumatol Clin (Engl Ed) ; 14(5): 303-306, 2018.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-28256443

RESUMO

Cat scratch disease (CSD) is an infectious disorder caused by Bartonella henselae and characterized by fever and granulomatous lymphadenopathy. Immunosuppression is a risk factor for the development of atypical forms of the disease. We report the case of a 52-year-old woman who presented with fever and bilateral inguinal lymph node enlargement. She did not have apparent contact with animals. The patient was receiving etanercept therapy for rheumatoid arthritis. Lymph node biopsy demonstrated granulomatous lymphadenitis. She was successfully managed by discontinuing etanercept and by treatment with minocycline. She developed clinical remission and typical seroconversion. Infection with Bartonella should be considered in the differential diagnosis in rheumatoid arthritis patients with lymphadenopathy of unknown origin.


Assuntos
Antirreumáticos/efeitos adversos , Artrite Reumatoide/tratamento farmacológico , Bartonella henselae/isolamento & purificação , Doença da Arranhadura de Gato/diagnóstico , Etanercepte/efeitos adversos , Hospedeiro Imunocomprometido , Antirreumáticos/uso terapêutico , Artrite Reumatoide/complicações , Artrite Reumatoide/imunologia , Doença da Arranhadura de Gato/imunologia , Etanercepte/uso terapêutico , Feminino , Humanos , Pessoa de Meia-Idade
3.
Rheumatol Int ; 32(1): 273-5, 2012 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-21243491

RESUMO

Human cytomegalovirus (CMV) is responsible for significant morbidity and mortality in immunocompromised populations, such as those suffering from dermatomyositis (DM). We present here a case study of a DM patient undergoing methotrexate treatment who presents with weakness, myalgia, elevated levels of hepatic transaminases and serological markers of CMV primo-infection. The antiviral activity of leflunomide against CMV was described recently. The use of leflunomide as an immunomodulator may have contributed to the satisfactory evolution of the treatment for a symptomatic CMV infection in an immunocompromised patient, since the typical treatment outcome is more prolonged and with additional complications.


Assuntos
Antivirais/uso terapêutico , Infecções por Citomegalovirus/tratamento farmacológico , Dermatomiosite/tratamento farmacológico , Imunossupressores/uso terapêutico , Isoxazóis/uso terapêutico , Metotrexato/uso terapêutico , Infecções Oportunistas/tratamento farmacológico , Antirreumáticos/uso terapêutico , Citomegalovirus , Infecções por Citomegalovirus/etiologia , Feminino , Humanos , Hospedeiro Imunocomprometido , Imunossupressores/efeitos adversos , Leflunomida , Metotrexato/efeitos adversos , Pessoa de Meia-Idade , Infecções Oportunistas/etiologia , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...